摘要
Mitochondrial DNA released from senescent tumor cells can activate STING signaling in polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), but rather than triggering an interferon response, it promotes immune suppression through a PERK-NF-κB pathway.Dr. Lai's recent study published in Immunity represents a deviation from the typical STING function and helps explain why senescence supports immune evasion [1].The cGAS-STING pathway is traditionally viewed as an activator of type I interferons and inflammatory cytokines through IRF3 and NF-κB, having therapeutic potential in the treatment of inflammatory and autoinflammatory diseases [2].However, Dr. Lai's study reveals that in the suppressive myeloid population of prostate tumors, STING plays an unexpected role [1].In PMN-MDSCs, the activation of cGAS-STING pathway promotes immune suppression instead of inflammation.Senescent tumor cells, induced by oncogenic stress or CDK4/6 inhibition, were found to release mitochondrial DNA through voltage-dependent anion channels.This DNA is packaged into extracellular vesicles and selectively taken up by PMN-MDSCs in the tumor microenvironment.Indeed, extracellular vesicles have importantly biology role in physiology and pathology [3, 4].Inside the cell, mtDNA activates the cGAS-STING pathway, but instead of going through IRF3 to produce interferons, STING engages the endoplasmic reticulum (ER) stress kinase PERK.The signaling axis operates in a cell-type specific way.In dendritic cells and macrophages, STING activation typically promotes interferon signaling, but IRF3 activation is low in PMN-MDSCs [5].In these cells, mtDNA activates a noncanonical STING pathway that bypasses IRF3 and instead utilizes PERK and NF-κB to induce immunosuppressive genes, including PD-L1, Arg1, and Nos2.This signaling depends on STING, PERK, and NF-κB, but not on IRF3, as inhibition of the former blocks the response while IRF3 deficiency has no effect.The study also helps explain why STING agonists exhibit heterogeneous effects in cancer therapy due to different